Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment
- Halozyme and Baxter Pharma have a Food and Drug Administration (FDA) Advisory Committee (adcom) meeting coming up on July 31.
- The adcom will give guidance on whether Halozyme's Biologics License Application (BLA) for its Human Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase (HyQvia) is acceptable in its new amended form.
- We believe the chance is about 80% for a positive adcom outcome.
- Additionally, Halozyme's proprietary PEGPH20 if ultimately FDA approved in time, would be a blockbuster treatment for Pancreatic Cancer, an open and large unmet need.